Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: JAZZ AXSM SUPN ACAD BMRN SRPT INCY IONS ALNY NVCR

| Held by: IJH VTI VB VBK VXF MDY XBI IBB VFLO FBT

Index	-	P/E	24.80	EPS (ttm)	6.50	Insider Own	2.71%	Shs Outstand	100.60M	Perf Week	9.73%
Market Cap	16.22B	Forward P/E	17.30	EPS next Y	9.32	Insider Trans	-2.95%	Shs Float	97.83M	Perf Month	23.32%
Enterprise Value	15.31B	PEG	0.49	EPS next Q	1.56	Inst Own	97.72%	Short Float	6.13%	Perf Quarter	17.37%
Income	668.60M	P/S	5.23	EPS this Y	61.68%	Inst Trans	1.36%	Short Ratio	5.19	Perf Half Y	7.53%
Sales	3.10B	P/B	4.76	EPS next Y	23.50%	ROA	15.56%	Short Interest	5.99M	Perf YTD	13.74%
Book/sh	33.87	P/C	12.32	EPS next 5Y	35.12%	ROE	22.50%	52W High	160.18 0.71%	Perf Year	38.03%
Cash/sh	13.09	P/FCF	19.51	EPS past 3/5Y	44.05% 2.31%	ROIC	17.53%	52W Low	116.00 39.07%	Perf 3Y	66.81%
Dividend Est.	-	EV/EBITDA	18.48	Sales past 3/5Y	24.32% 22.29%	Gross Margin	98.17%	Volatility	3.33% 2.89%	Perf 5Y	75.48%
Dividend TTM	-	EV/Sales	4.94	EPS Y/Y TTM	120.51%	Oper. Margin	25.75%	ATR (14)	4.61	Perf 10Y	269.58%
Dividend Ex-Date	-	Quick Ratio	2.85	Sales Y/Y TTM	28.59%	Profit Margin	21.55%	RSI (14)	81.32	Recom	1.37
Dividend Gr. 3/5Y	- -	Current Ratio	2.93	EPS Q/Q	2382.36%	SMA20	17.36%	Beta	0.36	Target Price	190.99
Payout	0.00%	Debt/Eq	0.12	Sales Q/Q	42.25%	SMA50	21.24%	Rel Volume	1.36	Prev Close	155.80
Employees	2000	LT Debt/Eq	0.12	Earnings	May 05 AMC	SMA200	16.94%	Avg Volume	1.15M	Price	161.32
IPO	May 23, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	57.05% 6.02%	Trades		Volume	1,564,390	Change	3.54%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-24-26	Initiated	Wolfe Research	Outperform	$160
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$175
Oct-21-25	Initiated	Citigroup	Buy	$175
Jul-21-25	Initiated	Truist	Buy	$163
Jul-10-25	Initiated	Goldman	Buy	$182
Apr-15-25	Upgrade	Needham	Hold → Buy	$138
Apr-14-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$137
Feb-11-25	Initiated	Deutsche Bank	Hold	$138
Oct-10-24	Resumed	Raymond James	Outperform	$155
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight	$131 → $159
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$140 → $170
Dec-13-23	Resumed	Citigroup	Neutral	$127
Dec-12-23	Initiated	Deutsche Bank	Buy	$136
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$135 → $140
Aug-21-23	Reiterated	Mizuho	Neutral	$112 → $113
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform	$115 → $125
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform	$91 → $96
May-04-23	Upgrade	Guggenheim	Neutral → Buy	$145
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy	$124 → $132
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform	$130

Show Previous Ratings

May-06-26 08:30AM	Neurocrine Biosciences, Inc. Q1 2026 Earnings Call Summary (Moby) +8.86%
08:30AM	Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia (PR Newswire)
May-05-26 04:14PM	Neurocrine: Q1 Earnings Snapshot (Associated Press)
04:01PM	Neurocrine Biosciences Reports First-Quarter 2026 Financial Results (PR Newswire)
09:00AM	Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026 (PR Newswire)
08:30AM	Loading…
May-04-26 08:30AM	Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment (PR Newswire)
07:30AM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist (PR Newswire)
May-01-26 04:05PM	Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia (PR Newswire)
Apr-29-26 04:05PM	Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale (PR Newswire)
Apr-22-26 04:05PM	Neurocrine Biosciences Presents New Two-Year CRENESSITY (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia (PR Newswire)
Apr-14-26 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results (PR Newswire)
08:30AM	Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA (valbenazine) Capsules Compared to AUSTEDO XR (PR Newswire)
Apr-07-26 09:47AM	Arm downgraded, Arista Networks upgraded: Wall Street's top analyst calls (The Fly)
05:21AM	Neurocrine to acquire Soleno in $2.9bn transaction (Hospital Management)
12:01AM	Neurocrine Scoops Up Hunger-Drug Maker in Latest Multi-Billion-Dollar Pharma Deal (The Daily Upside)
04:06PM	Loading…
Apr-06-26 04:06PM	Oil Climbs, Stocks Whipsaw After Trumps Warning: Markets Wrap (Bloomberg)
03:28PM	Neurocrine Agrees $2.9 Billion Soleno Deal At 34% Premium (GuruFocus.com)
09:35AM	Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal (Proactive)
08:58AM	SLNO Jumps As Deal Buzz Lifts Stocks (GuruFocus.com)
07:34AM	Neurocrine to Buy Soleno for $2.9 Billion (The Wall Street Journal)
07:24AM	This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal. (Barrons.com)
07:18AM	Soleno Therapeutics climbs on deal news, and more stocks on the move (MarketWatch)
07:04AM	Neurocrine wants to develop new obesity drugs. It's reportedly nearing an acquisition to accelerate that move. (MarketWatch)
07:00AM	Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio (PR Newswire)
Mar-26-26 08:30AM	Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings (PR Newswire)
Mar-17-26 04:05PM	Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer (PR Newswire)
Mar-10-26 04:01PM	Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum (PR Newswire)
Mar-06-26 05:00PM	BetterInvesting Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX) (PR Newswire)
Feb-27-26 09:37AM	Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Feb-24-26 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences in March (PR Newswire)
08:00AM	Loading…
08:00AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Blackstone, Blue Owl Capital, Booking Holdings, Cheniere Energy, Comcast, Dominos Pizza, KeyCorp, Qualcomm, and More (24/7 Wall St.)
Feb-23-26 04:28PM	Truist Lowers Neurocrine Biosciences, Inc.'s (NBIX) PT Following 2026 Outlook Update (Insider Monkey)
Feb-18-26 09:33PM	Needham Bullish on Neurocrine Biosciences, Inc. (NBIX) Pipeline Amid 2026 Growth Expectations for Crenessity and Ingrezza (Insider Monkey)
04:19AM	New Strong Sell Stocks for February 18th (Zacks)
Feb-12-26 02:38PM	Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance (Benzinga) -10.43%
12:23PM	Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor (BioPharma Dive)
08:30AM	Neurocrine Biosciences, Inc. Q4 2025 Earnings Call Summary (Moby)
12:04AM	Neurocrine Biosciences Inc (NBIX) Q4 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Feb-11-26 06:39PM	Neurocrine Biosciences Q4 Earnings Call Highlights (MarketBeat)
05:30PM	Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates (Zacks)
04:17PM	Neurocrine: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 (PR Newswire)
Feb-06-26 09:15AM	Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-05-26 10:00AM	Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
09:29AM	Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? (Zacks)
08:10AM	Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-04-26 10:00AM	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jan-26-26 08:30AM	Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia (PR Newswire)
Jan-22-26 12:10PM	Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive? (Zacks)
Jan-21-26 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results (PR Newswire)
Jan-15-26 08:30AM	Neurocrine Biosciences Presents Head-to-Head INGREZZA (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR (PR Newswire)
Jan-08-26 04:10PM	How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine (Investor's Business Daily)
08:09AM	Here Are Thursdays Top Wall Street Analyst Research Calls: Alphabet, Coinbase Global, Digital Realty Trust, Intuit, Reddit, Roku, Tyler Technologies, and More (24/7 Wall St.)
Jan-05-26 04:01PM	Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-22-25 04:05PM	Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy (PR Newswire)
Dec-16-25 04:01PM	Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology (PR Newswire)
Dec-09-25 04:01PM	Neurocrine Biosciences to Host R&D Day on December 16 (PR Newswire)
Dec-05-25 08:03AM	Leading Drug Stock Fights To Regain Buy Point At Key Resistance Level (Investor's Business Daily)
Nov-27-25 12:45PM	Here is Why Growth Investors Should Buy Neurocrine (NBIX) Now (Zacks)
Nov-26-25 04:11PM	Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied (Investor's Business Daily) +5.61%
Nov-20-25 08:30AM	Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA (valbenazine) Capsules (PR Newswire)
Nov-11-25 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
12:45PM	Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice (Zacks)
Nov-10-25 04:05PM	Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder (PR Newswire)
01:25PM	Neurocrine chalks up a depression drug failure (BioPharma Dive)
Nov-06-25 12:20PM	Earnings Estimates Rising for Neurocrine (NBIX): Will It Gain? (Zacks)
Nov-04-25 12:00PM	What Makes Neurocrine (NBIX) a New Strong Buy Stock (Zacks)
09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
Oct-30-25 04:15PM	Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
03:21PM	Neurocrine Biosciences Inc (NBIX) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
01:13PM	Earnings roundup: Alnylams down day, Neurocrines head scratch and Biogens low quality win (BioPharma Dive)
09:49AM	Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
Oct-29-25 04:14PM	Why Neurocrine Stock Was Spooked Despite Its Big Quarterly Beat (Investor's Business Daily) -6.35%
Oct-28-25 09:03PM	Neurocrine Biosciences Beats Estimates But Wall Street Punishes The Stock (24/7 Wall St.)
07:30PM	Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q3 Earnings (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates (Zacks)
04:45PM	Neurocrine Shares Rise, But Pull Back From Steep Gains, On Strong Ingrezza Quarter (Investor's Business Daily)
04:19PM	Neurocrine Bio Surges After Crushing Third-Quarter Expectations (Investor's Business Daily)
04:06PM	Neurocrine: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Third Quarter 2025 Financial Results (PR Newswire)
Oct-24-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Neurocrine Biosciences (NBIX) is a Great Choice (Zacks)
Oct-23-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX) (Zacks)
Oct-22-25 05:15PM	USANA Health Sciences (USNA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
10:00AM	United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-21-25 10:00AM	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-17-25 08:30AM	Neurocrine Biosciences Presents New KINECT 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA (valbenazine) 40 mg Capsules (PR Newswire)
Oct-07-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results (PR Newswire)
Oct-06-25 04:05PM	Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise (PR Newswire)
08:30AM	Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA (valbenazine) Capsules for Huntington's Disease Chorea (PR Newswire)
Sep-25-25 09:55AM	Should You be Optimistic on Neurocrine Biosciences (NBIX)? (Insider Monkey)
Sep-24-25 11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Sep-23-25 08:30AM	Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden (PR Newswire)
Sep-22-25 08:30AM	Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder (PR Newswire)
Sep-16-25 04:05PM	Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 (PR Newswire)
02:58PM	What Does Wall Street Think About Neurocrine Biosciences (NBIX)? (Insider Monkey)
Sep-02-25 04:03AM	Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access (Insider Monkey)
Aug-26-25 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences in September (PR Newswire)
Aug-20-25 11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Aug-12-25 10:16AM	Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Norwalk Leslie V	Director	May 12 '26	Proposed Sale	162.92	6,310	1,028,050		May 12 02:35 PM
ABERNETHY MATT	Chief Financial Officer	Feb 13 '26	Option Exercise	0.00	4,807	0	41,676	Feb 17 05:49 PM
ABERNETHY MATT	Chief Financial Officer	Feb 12 '26	Option Exercise	0.00	2,133	0	39,230	Feb 17 05:49 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 13 '26	Option Exercise	0.00	3,352	0	7,969	Feb 17 05:48 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 12 '26	Option Exercise	0.00	1,600	0	6,313	Feb 17 05:48 PM
Gano Kyle	Chief Executive Officer	Feb 13 '26	Option Exercise	0.00	4,807	0	147,610	Feb 17 05:48 PM
Gano Kyle	Chief Executive Officer	Feb 12 '26	Option Exercise	0.00	4,907	0	146,661	Feb 17 05:48 PM
Onyia Jude	Chief Scientific Officer	Feb 13 '26	Option Exercise	0.00	5,407	0	21,066	Feb 17 05:47 PM
Onyia Jude	Chief Scientific Officer	Feb 12 '26	Option Exercise	0.00	2,560	0	18,537	Feb 17 05:47 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 13 '26	Option Exercise	0.00	4,044	0	56,664	Feb 17 05:46 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 12 '26	Option Exercise	0.00	2,005	0	54,760	Feb 17 05:46 PM
Cooke Julie	Chief Human Resources Officer	Feb 13 '26	Option Exercise	0.00	2,911	0	30,395	Feb 17 05:46 PM
Cooke Julie	Chief Human Resources Officer	Feb 12 '26	Option Exercise	0.00	1,387	0	28,989	Feb 17 05:46 PM
Lippoldt Darin	Chief Legal Officer	Feb 13 '26	Option Exercise	0.00	4,100	0	51,628	Feb 17 05:45 PM
Lippoldt Darin	Chief Legal Officer	Feb 12 '26	Option Exercise	0.00	1,792	0	49,584	Feb 17 05:45 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 13 '26	Option Exercise	0.00	2,760	0	7,779	Feb 17 05:45 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 12 '26	Option Exercise	0.00	1,600	0	6,656	Feb 17 05:45 PM
GORMAN KEVIN CHARLES	Director	Feb 13 '26	Option Exercise	0.00	10,981	0	524,850	Feb 17 05:44 PM
Boyer David W.	Chief Corp. Affairs Officer	Jan 31 '26	Option Exercise	0.00	2,096	0	5,902	Feb 03 06:22 PM
BENEVICH ERIC	Chief Commercial Officer	Jan 31 '26	Option Exercise	0.00	2,294	0	54,047	Feb 03 06:21 PM
ABERNETHY MATT	Chief Financial Officer	Jan 31 '26	Option Exercise	0.00	2,437	0	38,465	Feb 03 06:06 PM
Cooke Julie	Chief Human Resources Officer	Jan 31 '26	Option Exercise	0.00	1,741	0	28,599	Feb 03 06:05 PM
Delaet Ingrid	Chief Regulatory Officer	Jan 31 '26	Option Exercise	0.00	801	0	5,531	Feb 03 06:04 PM
Gano Kyle	Chief Executive Officer	Jan 31 '26	Option Exercise	0.00	2,927	0	143,334	Feb 03 06:03 PM
GORMAN KEVIN CHARLES	Director	Jan 31 '26	Option Exercise	0.00	5,142	0	519,738	Feb 03 06:02 PM
Lippoldt Darin	Chief Legal Officer	Jan 31 '26	Option Exercise	0.00	2,373	0	49,127	Feb 03 06:01 PM
Onyia Jude	Chief Scientific Officer	Jan 31 '26	Option Exercise	0.00	238	0	16,119	Feb 03 06:01 PM
Gano Kyle	Chief Executive Officer	Jan 16 '26	Option Exercise	35.99	36,400	1,310,036	174,995	Jan 20 06:56 PM
Gano Kyle	Chief Executive Officer	Jan 16 '26	Sale	132.70	36,400	4,830,458	140,407	Jan 20 06:56 PM
KYLE GANO	Officer	Jan 16 '26	Proposed Sale	133.35	36,400	4,853,940		Jan 16 04:21 PM
Lippoldt Darin	Chief Legal Officer	Jan 08 '26	Option Exercise	35.99	3,349	120,531	46,754	Jan 12 04:18 PM
Norwalk Leslie V	Director	Dec 15 '25	Option Exercise	91.07	10,000	910,742	12,429	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 15 '25	Sale	152.23	5,000	761,144	7,429	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 16 '25	Sale	155.09	1,190	184,558	6,239	Dec 17 04:24 PM
Norwalk Leslie V	Director	Dec 15 '25	Proposed Sale	155.11	11,250	1,745,000		Dec 15 10:58 AM
Lippoldt Darin	Chief Legal Officer	Dec 08 '25	Option Exercise	43.24	4,376	189,218	47,781	Dec 10 09:04 AM
Lippoldt Darin	Chief Legal Officer	Dec 08 '25	Sale	159.65	4,376	698,615	43,405	Dec 10 09:04 AM
DARIN LIPPOLDT	Officer	Dec 08 '25	Proposed Sale	155.51	4,376	680,512		Dec 08 04:35 PM
LYONS GARY A	Director	Dec 03 '25	Option Exercise	47.89	15,000	718,350	135,482	Dec 04 04:14 PM
LYONS GARY A	Director	Dec 03 '25	Sale	152.61	15,000	2,289,082	120,482	Dec 04 04:14 PM
GARY A LYONS REVOCABLE LIVING	Director	Dec 03 '25	Proposed Sale	152.48	15,000	2,287,200		Dec 03 04:36 PM
BENEVICH ERIC	Chief Commercial Officer	Nov 28 '25	Option Exercise	35.99	5,970	214,860	50,863	Dec 02 05:21 PM
BENEVICH ERIC	Chief Commercial Officer	Nov 28 '25	Sale	151.74	5,970	905,881	44,893	Dec 02 05:21 PM
Onyia Jude	Chief Scientific Officer	Nov 29 '25	Option Exercise	0.00	4,426	0	18,129	Dec 02 05:14 PM
ERIC BENEVICH	Officer	Nov 28 '25	Proposed Sale	151.58	5,970	904,933		Nov 28 01:20 PM
MORROW GEORGE J	Director	Nov 25 '25	Option Exercise	47.89	15,000	718,350	22,068	Nov 26 04:28 PM
MORROW GEORGE J	Director	Nov 25 '25	Sale	143.37	15,000	2,150,512	7,068	Nov 26 04:28 PM
GEORGE MORROW	Director	Nov 25 '25	Proposed Sale	141.25	15,000	2,118,750		Nov 25 04:25 PM
RASTETTER WILLIAM H	Director	Nov 05 '25	Option Exercise	47.89	18,000	862,020	58,360	Nov 06 05:25 PM
RASTETTER WILLIAM H	Director	Nov 05 '25	Sale	151.82	18,000	2,732,690	40,360	Nov 06 05:25 PM
Gano Kyle	Officer	Nov 04 '25	Proposed Sale	141.97	300	42,591		Nov 05 09:09 PM
WILLIAM H. RASTETTER	Director	Nov 05 '25	Proposed Sale	143.19	18,000	2,577,420		Nov 05 04:19 PM
Gano Kyle	Chief Executive Officer	Nov 01 '25	Option Exercise	0.00	613	0	140,720	Nov 04 08:18 PM
Gano Kyle	Chief Executive Officer	Nov 04 '25	Sale	141.97	300	42,591	140,407	Nov 04 08:18 PM
GORMAN KEVIN CHARLES	Director	Aug 07 '25	Option Exercise	35.99	106,322	3,826,529	620,918	Aug 11 04:55 PM
GORMAN KEVIN CHARLES	Director	Aug 07 '25	Sale	126.41	106,322	13,440,281	514,596	Aug 11 04:55 PM
KEVIN CHARLES GORMAN	Director	Aug 07 '25	Proposed Sale	128.43	106,322	13,654,934		Aug 07 04:24 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '25	Option Exercise	79.02	457	36,112	5,187	Jul 11 05:15 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '25	Sale	135.00	457	61,695	4,730	Jul 11 05:15 PM
Onyia Jude	Chief Scientific Officer	Jul 09 '25	Option Exercise	84.74	59,819	5,069,062	78,108	Jul 11 05:01 PM
Onyia Jude	Chief Scientific Officer	Jul 09 '25	Sale	130.46	59,819	7,803,688	18,289	Jul 11 05:01 PM
INGRID DELAET	Officer	Jul 10 '25	Proposed Sale	133.51	457	61,014		Jul 10 04:32 PM
Onyia Jude	Chief Scientific Officer	Jul 02 '25	Option Exercise	84.74	20,362	1,725,476	38,651	Jul 07 04:10 PM
Onyia Jude	Chief Scientific Officer	Jul 02 '25	Sale	130.13	20,362	2,649,738	18,289	Jul 07 04:10 PM
JUDE ONYIA	Officer	Jul 02 '25	Proposed Sale	128.00	80,181	10,263,168		Jul 02 04:22 PM
GORMAN KEVIN CHARLES	Director	May 27 '25	Sale	120.38	9,613	1,157,211	514,596	May 29 06:15 PM
KEVIN CHARLES GORMAN	Director	May 27 '25	Proposed Sale	120.18	9,613	1,155,290		May 27 04:38 PM
RASTETTER WILLIAM H	Director	May 22 '25	Option Exercise	0.00	2,869	0	40,360	May 22 06:15 PM
POON CHRISTINE A	Director	May 22 '25	Option Exercise	0.00	1,435	0	1,435	May 22 05:32 PM
Sharp Shalini	Director	May 22 '25	Option Exercise	0.00	1,435	0	2,429	May 22 05:28 PM
SHERWIN STEPHEN A	Director	May 22 '25	Option Exercise	0.00	2,869	0	13,542	May 22 05:26 PM
POPS RICHARD F	Director	May 22 '25	Option Exercise	0.00	2,869	0	34,480	May 22 05:23 PM
MORROW GEORGE J	Director	May 22 '25	Option Exercise	0.00	2,869	0	7,068	May 22 05:20 PM
LYONS GARY A	Director	May 22 '25	Option Exercise	0.00	1,435	0	120,482	May 22 05:18 PM
Norwalk Leslie V	Director	May 22 '25	Option Exercise	0.00	1,435	0	2,429	May 22 05:14 PM
Mercier Johanna	Director	May 22 '25	Option Exercise	0.00	1,435	0	3,535	May 22 05:12 PM
Cooke Julie	Chief Human Resources Officer	May 16 '25	Option Exercise	61.82	6,468	399,852	26,858	May 20 04:43 PM

Open in Screener

TVTX

Travere Therapeutics Inc

May 13 • 04:00PM ET

44.55

+1.71 3.99 %

Healthcare • Biotechnology • USA • Mid • NASD

TVTX Travere Therapeutics Inc daily Stock Chart

Peers: VERA BCRX CPRX HRMY SLNO

| Held by: XBI VTI IWM VXF IBB IWO SCHA PJP VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-0.53	Insider Own	1.80%	Shs Outstand	92.40M	Perf Week	-0.47%
Market Cap	4.14B	Forward P/E	18.05	EPS next Y	2.47	Insider Trans	-32.47%	Shs Float	91.31M	Perf Month	5.74%
Enterprise Value	4.21B	PEG	-	EPS next Q	-0.05	Inst Own	111.45%	Short Float	15.57%	Perf Quarter	47.42%
Income	-45.64M	P/S	7.73	EPS this Y	215.60%	Inst Trans	1.87%	Short Ratio	6.68	Perf Half Y	29.58%
Sales	536.20M	P/B	41.70	EPS next Y	636.10%	ROA	-8.27%	Short Interest	14.22M	Perf YTD	16.59%
Book/sh	1.07	P/C	15.65	EPS next 5Y	-	ROE	-69.38%	52W High	48.61 -8.35%	Perf Year	112.75%
Cash/sh	2.85	P/FCF	104.59	EPS past 3/5Y	49.47% 30.85%	ROIC	-10.86%	52W Low	13.88 220.97%	Perf 3Y	182.14%
Dividend Est.	-	EV/EBITDA	261.39	Sales past 3/5Y	64.89% 19.87%	Gross Margin	84.94%	Volatility	5.76% 5.26%	Perf 5Y	135.71%
Dividend TTM	-	EV/Sales	7.84	EPS Y/Y TTM	82.27%	Oper. Margin	-10.64%	ATR (14)	2.37	Perf 10Y	189.10%
Dividend Ex-Date	-	Quick Ratio	3.08	Sales Y/Y TTM	96.03%	Profit Margin	-8.51%	RSI (14)	66.07	Recom	1.13
Dividend Gr. 3/5Y	- -	Current Ratio	3.13	EPS Q/Q	14.62%	SMA20	6.14%	Beta	1.12	Target Price	53.57
Payout	-	Debt/Eq	3.32	Sales Q/Q	55.63%	SMA50	29.00%	Rel Volume	1.20	Prev Close	42.84
Employees	497	LT Debt/Eq	3.26	Earnings	May 04 AMC	SMA200	49.05%	Avg Volume	2.13M	Price	44.55
IPO	Oct 06, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	-65.29% -6.63%	Trades		Volume	2,545,495	Change	3.99%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-14-26	Upgrade	Piper Sandler	Neutral → Overweight	$49
Oct-31-25	Reiterated	Citigroup	Buy	$34 → $48
Jun-11-25	Resumed	H.C. Wainwright	Buy	$30
Jun-11-25	Reiterated	Citigroup	Buy	$35 → $32
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Oct-21-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$9 → $27
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Upgrade	Guggenheim	Neutral → Buy	$25
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Nov-20-23	Initiated	Citigroup	Neutral	$7
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$24 → $8
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform	$30
Jul-21-23	Initiated	JP Morgan	Overweight	$26
Jun-07-23	Resumed	Piper Sandler	Neutral	$22
May-22-23	Initiated	TD Cowen	Outperform	$30
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy	$37
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform	$30

Show Previous Ratings

May-12-26 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-07-26 04:30PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
May-06-26 10:28PM	Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes (Business Wire)
May-05-26 04:01PM	Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes (Business Wire)
May-04-26 08:26PM	Travere Therapeutics, Inc. Q1 2026 Earnings Call Summary (Moby)
04:06PM	Loading…
04:06PM	Travere: Q1 Earnings Snapshot (Associated Press)
04:01PM	Travere Therapeutics Reports First Quarter 2026 Financial Results (Business Wire)
Apr-27-26 04:30PM	Travere Therapeutics to Report First Quarter 2026 Financial Results (Business Wire)
Apr-17-26 12:16PM	Four Biotech Stocks Near Buy Points As Earnings Season Kicks In (Investor's Business Daily)
Apr-14-26 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +37.23%
02:06PM	FDA approves first drug for rare kidney scarring disease (Quartz)
09:05AM	Travere Therapeutics Stock Skyrockets On FDA Approval (Investor's Business Daily)
08:07AM	Travere wins long-awaited approval for kidney disease drug (BioPharma Dive)
07:04AM	Travere Therapeutics gains FDA approval for sparsentan in FSGS (Pharmaceutical Business Review)
Apr-13-26 06:16PM	Travere Therapeutics Announces Full FDA Approval of FILSPARI (sparsentan), the First and Only Approved Medicine for FSGS (Business Wire) +6.01%
12:14PM	Loading…
Mar-10-26 12:14PM	VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study (Zacks)
08:02AM	Piper Sandler Increases Target Price for Travere Therapeutics (TVTX) (Insider Monkey)
Feb-24-26 10:18AM	Travere Therapeutics, Inc. (TVTX): A Bull Case Theory (Insider Monkey)
06:50AM	Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025 (Insider Monkey)
Feb-20-26 08:30AM	Travere Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
12:03AM	Travere Therapeutics Inc (TVTX) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-19-26 11:08PM	Travere Therapeutics Q4 Earnings Call Highlights (MarketBeat) +5.13%
05:30PM	Travere (TVTX) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:10PM	Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates (Zacks)
05:00PM	Travere Therapeutics posts surprise Q4 profit; Shares slip 5% on revenue miss (Investing.com)
04:15PM	Travere: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-18-26 01:10AM	Travere Therapeutics, Inc. (TVTX) Positioned for Long-Term Growth in Rare Disease Market (Insider Monkey)
Feb-17-26 10:00AM	Kiniksa Pharmaceuticals International, plc (KNSA) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-15-26 05:03PM	Travere Therapeutics Targets April FSGS FILSPARI Decision as IgAN Sales Accelerate, HCU Trial Restarts (MarketBeat)
04:30PM	Loading…
Feb-12-26 04:30PM	Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results (Business Wire) -9.08%
10:00AM	Travere Therapeutics (TVTX) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-11-26 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-04-26 04:30PM	Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit (Business Wire) -6.98%
Jan-28-26 05:35PM	Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +5.65%
Jan-22-26 09:52PM	BofA Remains Positive on Travere Despite FDA Decision Delay for Filspari (Insider Monkey) +5.24%
Jan-16-26 11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-14-26 10:54AM	TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA (Zacks)
06:44AM	Travere Stock Slips After FDA Delays Review Of Key Kidney Drug (Benzinga)
Jan-13-26 07:51PM	Why Travere Therapeutics Stock Got Trounced on Tuesday (Motley Fool) -14.63%
04:36PM	Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug (Investor's Business Daily)
04:35PM	Stocks Fall on Weakness in Software and Credit Card Companies (Barchart)
01:24PM	Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI (sparsentan) in FSGS (Business Wire)
11:19AM	Options Bears Eye Plummeting Biotech Stock (Schaeffer's Research)
11:17AM	Stock Indexes Slip as the Magnificent Seven Technology Stocks Retreat (Barchart)
09:54AM	Travere Therapeutics Hammered On A Potential, Surprise Delay For Filspari (Investor's Business Daily)
Jan-12-26 05:00PM	Travere Therapeutics Provides Corporate Update and 2026 Outlook (Business Wire)
Jan-05-26 04:30PM	Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) -6.06%
Dec-25-25 10:44AM	Dow Jones, S&P 500 Hit Record Highs. Stock Market Closed For Christmas. (Investor's Business Daily)
Dec-24-25 06:51PM	Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday (Motley Fool) +13.91%
04:40PM	Nvidia Buying AI Chip Startup Groq In Record $20 Billion Deal: CNBC (Investor's Business Daily)
01:40PM	Dow Jones, S&P 500 Hit Record Highs Heading Into Christmas Holiday (Investor's Business Daily)
Dec-18-25 10:41AM	Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? (Zacks)
Dec-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-26-25 08:00AM	Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 (Investor's Business Daily)
Nov-10-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.31% +5.03%
Nov-06-25 11:00AM	Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025 (Business Wire)
Nov-04-25 05:23PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
Nov-03-25 01:34AM	Travere Therapeutics (TVTX) Climbs 25% on Impressive Earnings (Insider Monkey)
Nov-01-25 02:48PM	Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook (Insider Monkey)
Oct-31-25 07:35PM	Closing Bell Movers: Amazon soars to all-time highs on earnings (TipRanks) +18.58%
04:06PM	Top 2% Travere Catapults To Profit-Taking Zone After Screaming Up Another Beat (Investor's Business Daily)
Oct-30-25 11:02PM	Travere Therapeutics Inc (TVTX) Q3 2025 Earnings Call Highlights: Strong FILSPARI Sales and ... (GuruFocus.com)
06:30PM	Travere (TVTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:55PM	Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:51PM	Travere: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Travere Therapeutics Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-29-25 09:41AM	Travere Therapeutics Inc (TVTX) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-27-25 06:58AM	Chugai acquires Renalys, enhancing its kidney disease portfolio (Pharmaceutical Technology) +6.09%
Oct-24-25 04:58AM	Chugai buys a kidney biotech; ICER targets rising launch prices (BioPharma Dive)
Oct-23-25 04:30PM	Travere Therapeutics to Report Third Quarter 2025 Financial Results (Business Wire)
12:22PM	Biotech Leader Travere Therapeutics Eyes Buy Point After More Than Doubling (Investor's Business Daily)
Oct-17-25 09:01AM	Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025 (Business Wire)
Oct-16-25 08:50AM	NVS Reports Positive Late-Stage Data on Kidney Disease Drug (Zacks)
Oct-15-25 12:00PM	What Makes Travere (TVTX) a New Strong Buy Stock (Zacks)
Oct-14-25 10:56AM	Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings? (Zacks)
Oct-10-25 05:11PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-26-25 07:00AM	CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy (Business Wire)
Sep-18-25 09:38AM	Target initiated, Nike upgraded: Wall Street's top analyst calls (The Fly)
Sep-12-25 01:16PM	Hims & Hers Leads 14 Growth Stocks Amid Medical Boom (Investor's Business Daily) -6.12%
Sep-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.46%
10:40AM	TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA (Zacks)
09:15AM	Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside (Insider Monkey)
04:57AM	Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength? (Zacks)
Sep-10-25 11:17AM	Stock Market Today: Inflation Data Hits Dow; Oracle Soars As This Biotech Zooms (Live Coverage) (Investor's Business Daily) +26.20%
09:13AM	Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High (Investor's Business Daily)
07:01AM	Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI (sparsentan) in FSGS (Business Wire)
Sep-03-25 07:01AM	Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism (Business Wire) +8.04%
Aug-28-25 10:00AM	Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch (Investor's Business Daily)
Aug-27-25 05:09PM	Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI (sparsentan) in IgA Nephropathy (Business Wire)
Aug-17-25 11:41PM	Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts (Insider Monkey)
Aug-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-08-25 09:06AM	Travere Therapeutics price target raised to $32 from $30 at Wedbush (TipRanks)
Aug-06-25 06:00PM	Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings (Zacks)
05:15PM	Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:13PM	Travere: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Travere Therapeutics Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-05-25 04:30PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
09:54AM	Earnings To Watch: Travere Therapeutics Inc (TVTX) Reports Q2 2025 Result (GuruFocus.com)
Jul-31-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Baynes Roy D.	Director	May 05 '26	Option Exercise	18.27	4,500	82,215	42,000	May 06 08:00 PM
Baynes Roy D.	Director	May 05 '26	Sale	46.65	4,500	209,925	37,500	May 06 08:00 PM
Meckler Jeffrey A	Director	May 04 '26	Option Exercise	16.33	8,000	130,640	95,500	May 06 08:00 PM
Meckler Jeffrey A	Director	May 04 '26	Sale	45.00	8,000	360,000	87,500	May 06 08:00 PM
ROTE WILLIAM E.	Chief Research Officer	May 04 '26	Option Exercise	0.00	4,250	0	118,237	May 06 08:00 PM
ROTE WILLIAM E.	Chief Research Officer	May 06 '26	Sale	43.95	2,763	121,434	115,474	May 06 08:00 PM
REED ELIZABETH E	Chief Legal Officer and GC	May 04 '26	Option Exercise	14.81	24,250	359,200	125,211	May 06 08:00 PM
REED ELIZABETH E	Chief Legal Officer and GC	May 04 '26	Sale	45.00	20,000	900,000	105,211	May 06 08:00 PM
REED ELIZABETH E	Chief Legal Officer and GC	May 05 '26	Sale	46.65	2,174	101,417	107,287	May 06 08:00 PM
REED ELIZABETH E	Chief Legal Officer and GC	May 06 '26	Sale	43.95	2,076	91,240	105,211	May 06 08:00 PM
Inrig Jula	CHIEF MEDICAL OFFICER	May 04 '26	Option Exercise	18.47	24,250	448,000	131,473	May 06 08:00 PM
Inrig Jula	CHIEF MEDICAL OFFICER	May 04 '26	Sale	45.00	20,000	900,000	111,473	May 06 08:00 PM
Inrig Jula	CHIEF MEDICAL OFFICER	May 05 '26	Sale	46.65	2,174	101,417	113,549	May 06 08:00 PM
Inrig Jula	CHIEF MEDICAL OFFICER	May 06 '26	Sale	43.95	311	13,668	113,238	May 06 08:00 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	May 04 '26	Option Exercise	0.00	4,250	0	142,858	May 06 08:00 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	May 05 '26	Sale	46.65	2,174	101,417	140,684	May 06 08:00 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	May 04 '26	Option Exercise	0.00	22,500	0	455,386	May 06 08:00 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	May 06 '26	Sale	43.95	22,500	988,875	432,886	May 06 08:00 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	May 04 '26	Option Exercise	0.00	4,250	0	121,149	May 06 08:00 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	May 05 '26	Sale	46.65	2,181	101,744	118,968	May 06 08:00 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	May 06 '26	Sale	43.95	310	13,624	118,658	May 06 08:00 PM
CHRISTOPHER CLINE	Officer	May 06 '26	Proposed Sale	43.95	310	13,624		May 06 04:03 PM
ELIZABETH REED	Officer	May 06 '26	Proposed Sale	43.95	2,076	91,240		May 06 04:03 PM
JULA INRIG	Officer	May 06 '26	Proposed Sale	43.95	311	13,668		May 06 04:02 PM
Dube Eric M	Officer	May 06 '26	Proposed Sale	43.95	22,500	988,875		May 06 09:55 AM
ROTE WILLIAM E.	Officer	May 06 '26	Proposed Sale	43.95	2,763	121,434		May 06 09:37 AM
Christopher Cline	Officer	May 05 '26	Proposed Sale	46.65	2,181	101,744		May 05 07:48 PM
Elizabeth E. Reed	Officer	May 05 '26	Proposed Sale	46.65	2,174	101,417		May 05 07:32 PM
Jula Inrig	Officer	May 05 '26	Proposed Sale	46.65	2,174	101,417		May 05 07:31 PM
Peter Heerma	Officer	May 05 '26	Proposed Sale	46.65	2,174	101,417		May 05 07:31 PM
ROY BAYNES	Director	May 05 '26	Proposed Sale	46.65	4,500	209,925		May 05 04:53 PM
Baynes Roy D.	Director	May 01 '26	Option Exercise	6.82	9,750	66,495	47,250	May 04 04:27 PM
Baynes Roy D.	Director	May 01 '26	Sale	44.22	9,750	431,145	37,500	May 04 04:27 PM
ELIZABETH REED	Officer	May 04 '26	Proposed Sale	45.00	20,000	900,000		May 04 04:04 PM
JEFFREY MECKLER	Director	May 04 '26	Proposed Sale	45.00	8,000	360,000		May 04 04:04 PM
JULA INRIG	Officer	May 04 '26	Proposed Sale	45.00	20,000	900,000		May 04 04:03 PM
ROY BAYNES	Director	May 01 '26	Proposed Sale	44.22	9,750	431,145		May 01 04:15 PM
ROTE WILLIAM E.	Chief Research Officer	Apr 22 '26	Sale	39.09	9,100	355,719	113,987	Apr 23 04:05 PM
ROTE WILLIAM E.	Officer	Apr 22 '26	Proposed Sale	39.09	9,100	355,719		Apr 22 10:36 AM
LYONS GARY A	Director	Apr 14 '26	Option Exercise	16.33	8,000	130,640	65,500	Apr 16 04:05 PM
LYONS GARY A	Director	Apr 14 '26	Sale	41.07	8,000	328,560	57,500	Apr 16 04:05 PM
Baynes Roy D.	Director	Apr 14 '26	Option Exercise	17.60	32,750	576,308	70,250	Apr 16 04:05 PM
Baynes Roy D.	Director	Apr 14 '26	Sale	41.29	32,750	1,352,130	37,500	Apr 16 04:05 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Apr 14 '26	Option Exercise	16.05	15,250	244,802	64,330	Apr 16 04:05 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Apr 14 '26	Sale	41.07	21,977	902,595	42,353	Apr 16 04:05 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Apr 14 '26	Sale	41.93	7,215	302,516	138,608	Apr 15 09:49 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Apr 15 '26	Sale	41.09	64,000	2,629,975	432,886	Apr 15 09:48 PM
REED ELIZABETH E	Chief Legal Officer and GC	Apr 14 '26	Option Exercise	17.76	37,500	665,950	156,711	Apr 15 09:47 PM
REED ELIZABETH E	Chief Legal Officer and GC	Apr 14 '26	Sale	41.21	44,715	1,842,641	111,996	Apr 15 09:47 PM
REED ELIZABETH E	Chief Legal Officer and GC	Apr 15 '26	Sale	41.83	6,785	283,810	105,211	Apr 15 09:47 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Apr 14 '26	Sale	41.93	7,248	303,892	117,913	Apr 15 09:46 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Apr 15 '26	Sale	42.61	1,014	43,207	116,899	Apr 15 09:46 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Apr 13 '26	Sale	28.85	65	1,875	125,161	Apr 15 09:46 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Apr 14 '26	Sale	41.93	7,215	302,516	112,491	Apr 15 09:46 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Apr 15 '26	Sale	42.61	1,018	43,377	111,473	Apr 15 09:46 PM
Dube Eric M	Officer	Apr 15 '26	Proposed Sale	41.09	64,000	2,629,833		Apr 15 04:16 PM
ELIZABETH REED	Officer	Apr 15 '26	Proposed Sale	41.83	6,785	283,823		Apr 15 04:15 PM
CHRISTOPHER CLINE	Officer	Apr 15 '26	Proposed Sale	42.61	1,014	43,207		Apr 15 04:14 PM
JULA INRIG	Officer	Apr 15 '26	Proposed Sale	42.61	1,018	43,377		Apr 15 04:13 PM
Elizabeth E. Reed	Officer	Apr 14 '26	Proposed Sale	41.93	7,215	302,516		Apr 14 09:17 PM
Jula Inrig	Officer	Apr 14 '26	Proposed Sale	41.93	7,215	302,516		Apr 14 08:53 PM
Peter Heerma	Officer	Apr 14 '26	Proposed Sale	41.93	7,215	302,516		Apr 14 08:47 PM
Christopher Cline	Officer	Apr 14 '26	Proposed Sale	41.93	7,239	303,522		Apr 14 08:40 PM
GARY A LYONS	Officer	Apr 14 '26	Proposed Sale	30.70	8,000	245,600		Apr 14 04:27 PM
CHRISTOPHER CLINE	Officer	Apr 14 '26	Proposed Sale	41.07	9	370		Apr 14 04:20 PM
ELIZABETH REED	Officer	Apr 14 '26	Proposed Sale	41.07	37,500	1,540,125		Apr 14 04:19 PM
ROY BAYNES	Director	Apr 14 '26	Proposed Sale	41.29	32,750	1,352,130		Apr 14 04:09 PM
SANDRA CALVIN	Officer	Apr 14 '26	Proposed Sale	41.07	21,977	902,595		Apr 14 04:02 PM
Christopher Cline	Officer	Apr 13 '26	Proposed Sale	28.85	65	1,875		Apr 13 08:11 PM
Baynes Roy D.	Director	Apr 06 '26	Option Exercise	26.52	10,000	265,200	47,500	Apr 07 06:17 PM
Baynes Roy D.	Director	Apr 06 '26	Sale	33.00	10,000	330,000	37,500	Apr 07 06:17 PM
ROY BAYNES	Director	Apr 06 '26	Proposed Sale	33.00	10,000	330,000		Apr 06 04:06 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Apr 01 '26	Option Exercise	15.46	60,000	927,600	492,886	Apr 02 05:55 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Apr 01 '26	Sale	30.93	60,000	1,855,839	432,886	Apr 02 05:55 PM
REED ELIZABETH E	Chief Legal Officer and GC	Apr 01 '26	Option Exercise	15.46	10,000	154,600	115,211	Apr 02 05:55 PM
REED ELIZABETH E	Chief Legal Officer and GC	Apr 01 '26	Sale	30.00	10,000	300,000	105,211	Apr 02 05:55 PM
Dube Eric M	Officer	Apr 01 '26	Proposed Sale	30.93	60,000	1,855,655		Apr 01 04:13 PM
ELIZABETH REED	Officer	Apr 01 '26	Proposed Sale	30.00	10,000	300,000		Apr 01 04:06 PM
REED ELIZABETH E	Chief Legal Officer and GC	Mar 16 '26	Option Exercise	19.08	10,000	190,800	115,211	Mar 18 04:05 PM
REED ELIZABETH E	Chief Legal Officer and GC	Mar 16 '26	Sale	28.09	10,000	280,861	105,211	Mar 18 04:05 PM
ELIZABETH REED	Officer	Mar 16 '26	Proposed Sale	28.09	10,000	280,861		Mar 16 04:20 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Feb 20 '26	Option Exercise	15.46	60,000	927,600	492,886	Feb 24 04:05 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Feb 20 '26	Sale	30.10	60,000	1,805,766	432,886	Feb 24 04:05 PM
Dube Eric M	Officer	Feb 20 '26	Proposed Sale	30.10	60,000	1,805,766		Feb 20 04:49 PM
REED ELIZABETH E	Chief Legal Officer and GC	Feb 17 '26	Option Exercise	19.08	10,000	190,800	115,211	Feb 19 04:10 PM
REED ELIZABETH E	Chief Legal Officer and GC	Feb 17 '26	Sale	27.83	10,000	278,315	105,211	Feb 19 04:10 PM
ELIZABETH REED	Officer	Feb 17 '26	Proposed Sale	27.83	10,000	278,317		Feb 17 04:30 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 04 '26	Sale	32.21	1,779	57,295	105,706	Feb 05 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Feb 04 '26	Sale	32.19	1,745	56,168	111,226	Feb 05 04:05 PM
REED ELIZABETH E	Chief Legal Officer and GC	Feb 04 '26	Sale	32.18	2,994	96,359	105,211	Feb 05 04:05 PM
ELIZABETH REED	Officer	Feb 04 '26	Proposed Sale	32.18	2,994	96,360		Feb 04 04:07 PM
JULA INRIG	Officer	Feb 04 '26	Proposed Sale	32.21	1,779	57,299		Feb 04 04:06 PM
CHRISTOPHER CLINE	Officer	Feb 04 '26	Proposed Sale	32.19	1,745	56,166		Feb 04 04:01 PM
Peter Heerma	Officer	Feb 03 '26	Proposed Sale	32.12	7,310	234,799		Feb 04 06:00 AM
Elizabeth E. Reed	Officer	Feb 03 '26	Proposed Sale	32.12	7,175	230,464		Feb 03 09:59 PM
Sandra Calvin	Officer	Feb 03 '26	Proposed Sale	32.12	4,333	139,177		Feb 03 09:58 PM
Christopher Cline	Officer	Feb 03 '26	Proposed Sale	32.12	7,242	232,616		Feb 03 09:45 PM
Jula Inrig	Officer	Feb 03 '26	Proposed Sale	32.12	6,956	223,429		Feb 03 09:37 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Feb 03 '26	Sale	32.28	100,087	3,230,316	432,886	Feb 03 09:30 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 03 '26	Sale	32.12	6,956	223,427	107,485	Feb 03 09:30 PM

NBIX

Neurocrine Biosciences Inc

TVTX

Travere Therapeutics Inc

Upgrade your Finviz experience